FDA Approves Pimjetmi (Pimicotinib) for Patients With Tenosynovial Giant Cell Tumor by Madaline Spencer| Published on: Nov 12, 2026

FDA Approves Pimjetmi (Pimicotinib) for Patients With Tenosynovial Giant Cell Tumor by Madaline Spencer| Published on: Nov 12, 2026 The US Food and Drug Administration (FDA) has approved Pimjetmi (pimicotinib) as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. https://checkrare.com/fda-approves-pimjetmi-pimicotinib-for-patients-with-tenosynovial-giant-cell-tumor/